Clinical Trials

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasms

NCT00433420 2024-05-08

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

2,000 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT01996267 2024-03-29

TRAIN-2

437 enrolled

Breast Neoplasms

NCT00630032 2024-02-21

TavIx

762 enrolled 14 charts

Breast Neoplasms

NCT00309478 2023-06-29

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

1,099 enrolled

Breast Neoplasms

NCT00121992 2023-04-04

Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

1,060 enrolled 20 charts

Breast Neoplasms

NCT00129389 2023-03-07

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

1,925 enrolled 19 charts

Breast Neoplasms

NCT00129922 2023-03-06

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

1,289 enrolled

Breast Neoplasms

NCT00087178 2022-08-11

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

2,722 enrolled 14 charts

Breast Neoplasms

NCT00309569 2020-10-14

Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients

429 enrolled

Breast Neoplasms

NCT00625898 2020-09-10

BETH

Phase 3 Terminated

3,509 enrolled

Breast Neoplasms

NCT02879513 2020-03-23

Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

290 enrolled

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT04127019 2020-02-26

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

2,079 enrolled

Primary Breast Cancer

NCT02115204 2019-10-03

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

2,011 enrolled

Breast Neoplasms

NCT02995772 2019-06-19

Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

122 enrolled

Breast Neoplasms

NCT00301925 2018-08-08

TACT2

4,400 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT00950300 2018-01-23

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

596 enrolled 31 charts 1 FDA

Breast Neoplasms

NCT02001506 2017-08-29

Neo-shorter

250 enrolled

Breast Neoplasms

NCT01222052 2017-06-26

NNBC3-Europe

4,150 enrolled

Breast Neoplasms

NCT00331097 2017-03-28

ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment

300 enrolled

Breast Neoplasms

NCT00544232 2016-02-15

Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)

720 enrolled

Breast Neoplasms

NCT02450058 2015-05-21

MIG5

1,055 enrolled

Breast Neoplasms

NCT00002870 2014-12-16

High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer

180 enrolled

Breast Neoplasms

NCT00053911 2014-12-16

Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer

Phase 3 Terminated

Breast Neoplasms

NCT01985724 2014-05-14

Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

650 enrolled

Breast Neoplasms

NCT00003577 2013-12-19

Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer

2,000 enrolled

Breast Neoplasms

NCT00003893 2013-12-19

Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer

2,250 enrolled

Breast Neoplasms

NCT00005581 2013-12-18

Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

1,000 enrolled

Breast Neoplasms

NCT00002579 2013-11-06

Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer

2,000 enrolled

Breast Neoplasms

NCT00002580 2013-11-06

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

1,000 enrolled

Breast Neoplasms

NCT00002581 2013-11-06

Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer

1,000 enrolled

Breast Neoplasms

NCT00002755 2013-11-06

Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

600 enrolled

Breast Neoplasms

NCT00003680 2013-11-06

Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer

300 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00017095 2013-10-24

Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer

1,856 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00003013 2013-09-17

Chemotherapy Plus Surgery in Treating Women With Breast Cancer

450 enrolled

Breast Neoplasms

NCT00963729 2013-08-12

Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery

756 enrolled

Breast Neoplasms

NCT00629278 2013-08-07

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

2,500 enrolled

Breast Neoplasms

NCT00002696 2013-08-02

Combination Chemotherapy in Treating Women With Stage III Breast Cancer

Phase 3 Suspended

Breast Neoplasms

NCT01031030 2013-08-02

Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)

800 enrolled

Breast Neoplasms

NCT00054587 2013-07-19

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

3,010 enrolled

Breast Neoplasms

NCT00311636 2013-06-26

Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery

280 enrolled

Breast Neoplasms

NCT00055679 2013-06-18

Combination Chemotherapy in Treating Women With Stage I Breast Cancer

1,512 enrolled

Breast Neoplasms

NCT00047099 2013-05-30

Combination Chemotherapy in Treating Women With Breast Cancer

446 enrolled

Breast Neoplasms

NCT00002784 2013-04-04

15-95

344 enrolled

Breast Neoplasms

NCT00929591 2013-01-24

SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer

1,558 enrolled

Breast Neoplasms

NCT00038402 2012-07-20

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

74 enrolled

Breast Neoplasms

NCT00336791 2012-02-14

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

273 enrolled

Breast Neoplasms

NCT00152178 2011-07-07

The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)

680 enrolled

Breast Neoplasms

NCT00193011 2011-05-03

Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer

150 enrolled